Functioning Pharmacovigilance is the safety of treatment!

 

The main purpose of MISTRAL CAPITAL MANAGEMENT LIMITED is to ensure the highest quality and duly safety of medicinal products.

The company MISTRAL CAPITAL MANAGEMENT LIMITED has a system of Pharmacovigilance to monitor the safety of medicines. In accordance with the international standards and Pharmacovigilance legislation of countries where the company MISTRAL CAPITAL MANAGEMENT LIMITED is responsible to monitor the safety and efficacy of medicinal products, the system ensures the implementation of all necessary measures at the national and internationals levels.  

Pharmacovigilance is the process related to the detection, collection, evaluation, study and prevention of adverse reactions, adverse events after immunization / tuberculin testing and any other issues related to the safety and efficacy of medicines, vaccines, tuberculin.

 

Adverse effect is any unintentional adverse reaction to the drug; any unintentional adverse reaction to the vaccine, tuberculin, if it is caused or accelerated by the active ingredient (one of the other components) or is associated with abnormalities during the manufacture of the vaccine, tuberculin, including the delivery device provided by the manufacturer.

Proper quality of medicinal products is not an absolute assurance that any adverse reactions will not occur when administrating any medicine that caused by pharmacological properties of medicine components or peculiarities of body response. These are the issues the Pharmacovigilance deals with. 

Pharmacovigilance allows to monitor the safety of medicines throughout the life cycle (both when developing and in the post-registration period). Taking into account such information, it makes possible to detect the changes of benefit/risk ration, minimize the side effects of the medicine or reduce its impact. Implementation of risk minimization measures, allows the patient to receive the most suitable treatment.   

That is why any information about the safety of medicines of MISTRAL CAPITAL MANAGEMENT LIMITED is very important to us!

If you have learned about:

- adverse reaction;

- lack of therapeutic effect;

- notifications on overdose, abuse, misuse, medical mistakes and influence associated with nature of professional activity;

- transmission of the pathogen through the drug;

- side effects during pregnancy or breastfeeding;

- impact on embryo or fetus (when used by mother or via transmission of the medicinal product through father’s sperm):

- unexpected therapeutic effect;

- interaction with other medicinal products;

- suspected adverse events associated with the quality defect or adulteration of the medicine

of the company MISTRAL CAPITAL MANAGEMENT LIMITED, please find the opportunity to inform us in a way convenient for you, indicated below.

 

It is important to indicate in the message:

1. Contact details of the person who made the notification (name, phone number, country,       e-mail address, qualification, for example, doctor or non-medical personnel).
2. Information about the person who used the medicine (name, age, sex, etc.) 
3. Information about the used medicine (trade name, dose, administration period, batch number (compulsory for biological preparations), etc.).
4. Describe the problem associated with the medicine administration (adverse event and/or other safety problem).

If you do not have the complete information, please inform us about any problem associated with administration of the medicine of the company MISTRAL CAPITAL MANAGEMENT LIMITED. 

Contacts in Ukraine*:

Phone: +38 099 770 85 22 – round the clock

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Correspondence address: Ukraine 03022, Kyiv, 1 Sumska Str., PO Box 21

Contacts in the Republic of Uzbekistan*:

Phone: +9 9890 187 5953

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. 

Contacts in the Republic of Kazakhstan*:

Phone: +7 708 930 12 80

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

* Notifications are accepted on the basis of duly executed contractual legal relations by the Qualified Person Responsible for Pharmacovigilance (QPPV) and Responsible Person for Pharmacovigilance (RPPV) of the company MISTRAL CAPITAL MANAGEMENT LIMITED.

To inform about safety problem, please fill in the forms:

Adverse drug reaction form for consumers

Adverse drug reaction form for medical professionals

Before informing about the side effect of the medicine, please read Regulation on the confidentiality, which is the granting of permission for the processing of your / consumer’s personal data to the extent necessary and sufficient for Pharmacovigilance.

We will be grateful for your message!